Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
Ernest NadalDolores BautistaLuis Cabezón-GutiérrezAna Laura OrtegaHéctor-Enrique Torres-RivasDavid CarcedoLucía Ruiz de AldaJ Francisco GarciaPaula VieitezFederico RojoPublished in: BMC cancer (2021)
ALK testing in advanced NSCLC patients, non-squamous and never-smoker squamous, provides more than 3000 QALYs in Spain over a lifetime horizon. Comparing this gain in health outcomes with the incremental costs, the resulting incremental cost-effectiveness ratio reinforces that testing non-squamous and never-smoker squamous NSCLC is a cost-effective strategy in Spain.